Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Here's Why

Key Points

• Vaxart's stock price has recently fallen below its 200-day moving average, trading at $0.36 compared to the average price of $0.42.
• The company has a market capitalization of $82.90 million and a PE ratio of -1.34, indicating ongoing financial challenges.
• Significant institutional investment activity has occurred, with firms like Jones Financial Companies increasing their holdings by over 276,000%, showcasing potential confidence in the company's future.

Vaxart, Inc. (NASDAQ:VXRT - )'s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.42 and traded as low as $0.36. Vaxart shares last traded at $0.36, with a volume of 370,407 shares trading hands.

Vaxart Trading Down 2.1%

The stock has a market capitalization of $82.90 million, a PE ratio of -1.34 and a beta of 1.33. The firm has a 50-day moving average price of $0.38 and a 200-day moving average price of $0.42.

Institutional Investors Weigh In On Vaxart

Several large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in shares of Vaxart in the 2nd quarter worth approximately $794,000. Squarepoint Ops LLC raised its stake in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after buying an additional 251,789 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after buying an additional 478,111 shares during the last quarter. Raymond James Financial Inc. lifted its position in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock valued at $107,000 after buying an additional 34,075 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 17,942 shares during the period. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.